Shionogi Weighs Making Antibiotics in US Amid Rising Tariffs

Shionogi & Co. is weighing producing its antibiotic Fetroja in the US as the pharma industry comes under pressure from President Donald Trump’s tariffs.

The Japanese drugmaker is “actively” considering the option, with a goal of starting supply during the Trump administration, though no decision has been made on a site or investment, according to a spokesman. The company expects the medicine - used to treat multi-drug resistance bacterial infection - to become a key product as cases of antimicrobial resistance, or AMR, increase.